Richard H. Simon, M.D.

Professor of Internal Medicine,

Division of Pulmonary and Critical Care Medicine

University of Michigan Health System

1150 W. Medical Center Drive, 6301 MSRB III

Ann Arbor, MI, 48109-5642

(734) 936-5047; fax (734) 764-2655

richsimo@umich.edu

Title and Contents 1

[Education and Training 2](#_Toc147719855)

[Certification and Licensure 2](#_Toc147719856)

[Academic, Administrative, and Clinical Appointments 3](#_Toc147719857)

[Research Interests 3](#_Toc147719858)

[Grants 3](#_Toc147719859)

[Honors and Awards 5](#_Toc147719860)

[Memberships in Professional Societies 5](#_Toc147719861)

[Editorial Positions, Boards, and Peer-Review Services 5](#_Toc147719862)

[Teaching 8](#_Toc147719863)

[Committee, Organizational, and Volunteer Services 9](#_Toc147719864)

[Consulting Positions 12](#_Toc147719865)

[Visiting Professorships, Seminars, and Extramural Invited Presentations 12](#_Toc147719866)

[Bibliography 15](#_Toc147719867)

Richard H. Simon, M.D.

Professor of Internal Medicine,

Division of Pulmonary and Critical Care Medicine

University of Michigan Health System

1150 W. Medical Center Drive, 6301 MSRB III

Ann Arbor, MI, 48109-5642

(734) 936-5047; fax (734) 764-2655

richsimo@umich.edu

# Education and Training

9/1961 – 6/1965 George A. Dondero High School, Royal Oak, MI

9/1965 – 5/1969 University of Michigan, Ann Arbor, MI; B.S.

7/1969 – 8/1972 Duke University School of Medicine, Durham, NC; M.D.

9/1972 - 3/1973 Research Fellow, Division of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, NC; Mentors Jaqueline Reynolds, Ph.D. and Charles Tanford, Ph.D.

7/1973 – 6/1974 Intern, Straight Medicine, H.C. Moffitt Hospital, University California San Francisco, San Francisco, CA

7/1974 – 6/1975 Resident, Straight Medicine, University of California San Francisco Affiliated Hospitals, San Francisco, CA

07/1975 – 06/1977 US Public Health Service, National Institutes of Health, Bethesda, MD (Military Service; honorable discharge)

07/1975 – 06/1977 Research Associate, Laboratory of Molecular Biology, National Institute of Arthritis, Metabolic, and Digestive Diseases, National Institutes of Health, Bethesda, MD; Mentor: Gary Felsenfeld, Ph.D.

07/1977 – 06/1978 Chief Medical Resident, Department of Internal Medicine, University of Colorado Health Sciences Center, Denver, CA

07/1978 – 06/1981 Pulmonary Fellow, Division of Pulmonary Medicine, University of Colorado Health Sciences Center, Denver, CA

07/1979 – 06/1981 Research Fellow, Eleanor Roosevelt Institute for Cancer Research, University of Colorado Health Sciences Center, Denver, CA; Mentors: Charles H. Scoggin, M.D., David Patterson, Ph.D.

7/1980 – 6/1981 Waring Senior Fellow, Francis S. North Foundation

# Certification and Licensure

1976 American Board of Internal Medicine
Internal Medicine

1980 American Board of Internal Medicine
Pulmonary Diseases

1981- Medical Licensure: Michigan, #43736

# Academic, Administrative, and Clinical Appointments

### *Academic Appointments*

06/1981 – 08/1989 Assistant Professor, Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, MI

09/1989 – 08/1996 Associate Professor, Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, MI

09/1996 – present Professor, Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, MI

### *Administrative Appointments*

08/1995 – 03/1998 Associate Chair of Internal Medicine for Clinical Programs

10/2007 – present Associate Chair of Internal Medicine for Faculty Affairs

### *Clinical Appointments*

06/1981 – 08/2013 Staff Physician, Division of Pulmonary and Critical Care Medicine, Veterans Administration Medical Center, Ann Arbor, MI

06/1981 – present Staff Physician, University Hospital, Ann Arbor, MI

# Research Interests

1. Lung injury and repair
2. Pulmonary fibrosis
3. Plasminogen activator system in tissue fibrosis
4. Cystic fibrosis

# Grants

## Present and Active

 Cystic Fibrosis Foundation

 “Data Safety Monitoring Board”

 Richard H. Simon, Associate Chair (15% effort)

 10/01/2007 – present

## Major Previous Grants

 National Institutes of Health, NHLBI, R01 HL078871

 “The Antiprotease and Vitronectin-Binding Functions of PAI-1 in Lung Fibrosis”

 Thomas H. Sisson, principal investigator

 Richard H. Simon, Co-investigator (5% effort)

 5/1/2007 4/30/2012

 National Institutes of Health, NHLBI, PO HL31963

 "Inflammatory Cells and Lung Injury"

 Program Director: Dr. Peter A. Ward

 Section VI: "Basement Membrane Matrix in Lung Injury",

 Dr. Paul Killen, P.I.

 3/1/89 - 2/28/94

 (945,259 annual direct cost, Dr. Simon 15% effort)

 National Institutes of Health, NHLBI, P50 HL46487

 "SCOR in Occupational and Immunological Lung Diseases"

 Program Director: Dr. Galen B. Toews

 Project 3: "Lung Alveolar Epithelial Cells and Fibrinolysis"

 Dr. Richard Simon, P.I. (20% effort)

 12/1/91 - 11/30/96

 ($5,827,001 total program direct costs, $693,996 annual direct costs)

 National Institutes of Health, NHLBI, P50 HL56402 (Years 01-05)

 "SCOR in the Pathobiology of Fibrotic Lung Disease"

 Program Director: Dr. Galen B. Toews

 Project 4: "Gene Transfer of Fibrinolytic Agents in Lung Fibrosis"

 Dr. Richard Simon, P.I. (30% effort)

 12/1/96 - 11/30/01

 ($835,094 total direct costs, $174,816 annual direct costs)

 National Institutes of Health, NHLBI, P50 HL56402 (Years 06-10)

 "SCOR in the Pathobiology of Fibrotic Lung Disease"

 Program Director: Dr. Galen B. Toews

 Project 3: "The Plasminogen Activation System in PulmonaryFibrosis"

 Dr. Richard Simon, P.I. (30% effort)

 12/1/01 - 11/30/06

 ($1,129,480 total direct costs, $212,743 annual direct costs)

 Cystic Fibrosis Foundation

 “Gene Modifier Study”, a multicenter study

 Richard H. Simon, site principal investigator (0% effort)

 03/01/02 – 12/28/11

 $6,000 total costs

 National Institutes of Health, NIH R01 HL 94311

 “Control of Fibroblast Function by Prostaglandin E2 and Plasminogen Activation”

 Marc Peters-Golden, principal investigator

 Richard H. Simon, Co-investigator (5% effort)

 8/11/2009 -- 6/30/2012

 $379,710 annual direct costs

# Honors and Awards

1969 Phi Beta Kappa, University of Michigan Chapter

1972 Alpha Omega Alpha, Duke University Chapter

1985 – 1987, 1989 Designated by departing internal medicine senior residents as being in the "top ten of the faculty" for 1985, 1986, 1987, and 1989 (list no longer compiled after 1989).

1995 H. Marvin Pollard Award for Outstanding Resident Teaching, Dept. of Internal Medicine; awarded annually to a single faculty member

1998 Chairman’s Award for outstanding service to the Department; awarded annually to a single faculty member

2007 Cystic Fibrosis Foundation; Volunteer recognition award

2008 Outstanding Faculty Award presented by the graduating fellowship class of the Pulmonary/Critical Care Medicine Division

# Memberships in Professional Societies

1981 – 1992 American Federation Clinical Research

1981 – 1997, 2002 American Thoracic Society

1987 – present American Association for the Advancement of Science

1983 – 1989 American Heart Association

1987 – 1997 Central Society for Clinical Research

1981 – 1999 Michigan Thoracic Society

1985 – 1991 American College of Chest Physicians, Michigan Chapter

1987 – 2000 American Physiological Society

1997 – 2000 American Society of Gene Therapy

# Editorial Positions, Boards, and Peer-Review Services

## Editorial Boards

Reviewer

 *American Journal of Pathology*

 *American Review Respiratory Diseases*

 *American Journal of Respiratory and Critical Care Medicine*

 *American Journal of Respiratory Cell and Molecular Biology*

 *American Journal of Physiology: Lung*

 *American Journal of Physiology: Renal*

 *Archives of Internal Medicine*

 *Blood*

 *BMC Pulmonary Medicine*

 *British Journal of Pharmacology*

 *Chest*

 *European Respiratory Journal*

 *FASEB Journal*

 *Gene Therapy*

 *Human Gene Therapy*

 *Journal of Biological Chemistry*

 *Journal of Clinical Investigation*

 *Journal of Gene Therapy*

 *Journal of Immunology*

 *Journal of Infectious Diseases*

 *Journal of Investigative Medicine*

 *Journal of Laboratory and Clinical Medicine*

 *Journal of Leukocyte Biology*

 *Laboratory Investigation*

 *Lung*

 *Molecular Therapy*

 *New England Journal of Medicine*

 *Respiration*

 *Respiratory Medicine*

 *Thrombosis and Haemostasis*

## Study Sections

10/1988 Ad hoc reviewer for Clinical Investigator and Physician Scientist Awards, National Heart Lung Blood Institute, National Institutes of Health

02/1990 Ad hoc reviewer for Program Project Grant, National Heart Lung Blood Institute, National Institutes of Health

10/1990, 10/1991, Ad hoc reviewer for Research Training Review Committee, National
 03/1992, 08/1992, Heart Lung Blood Institute, National Institutes of Health
 02/1993

12/90 Ad Hoc Reviewer, Program Project Grant NIDDKD, National Institutes of Health

06/1991, 02/1996 Ad Hoc reviewer, Lung Biology and Pathology Study, National Institutes of Health

02/1993 Reviewer for Group Grant application, Medical Research Council of Canada, site visit, Toronto, Canada

03/1994 Ad Hoc reviewer for Clinical Investigator Development Awards, National Heart Lung Blood Institute, National Institutes of Health

071994, 09/1994 Reviewer, for Pilot Grants and Post-Doctoral Fellowships, Cystic Fibrosis Center for Gene Therapy, University of Pennsylvania

08/1994 Ad Hoc reviewer for Veterans Administration Merit Review Applications

11/94, 10/95 Ad Hoc reviewer for Canadian Cystic Fibrosis Foundation

05/1995 Ad Hoc reviewer for the Medical Research Council of Canada

07/1995 Ad Hoc reviewer for the British Columbia Health Research Foundation

10/1995 – 09/2002 Cystic Fibrosis Foundation Center Site visitor

03/1996 Site visitor, NIH CRC application, Cincinnati, OH

06/1996 Ad hoc reviewer for RFA: Pathogenesis and Treatment of Cystic Fibrosis, NIDDK

12/1996 NIH Minority Award study section

02/1997 Reviewer for Program Project Grant NCI, National Institutes of Health

07/1997 Reviewer for Gene Therapy Grants RFP, NHLBI, National Institutes of Health

01/1998 Reviewer for Program Project Grants, NHLBI, National Institutes of Health

09/1998 Reviewer for Program Project Grants, NHLBI, National Institutes of Health

11/98 Reviewer for Special Study Section, Department of Grant Reviews, National Institutes of Health

03/1999 Reviewer for NIH small business study section "Drug development and delivery" (ZRG1 SSSZ(1)), National Institutes of Health

06/2001 Reviewer, Quality Improvement Awards, Cystic Fibrosis Foundation, Bethesda, MD

09/2001 Reviewer, for Pilot Grants and Post-Doctoral Fellowships, Cystic Fibrosis Center for Gene Therapy, University of Pennsylvania

12/2001 Reviewer, General Clinical Research Center, University of Michigan

05/2002 Reviewer, British Columbia Research Grants, Vancouver, BC

09/2002 Reviewer, K23 & K25 awards, NHLBI, National Institutes of Health

11/2002 Reviewer, Canadian Institutes of Health Research, Ottawa, ON

03/2003 Reviewer, John Sealy Memorial Endowment for Clinical Research, Galveston, TX

10/07/2003 Reviewer, for Program Project Grant, NHLBI, National Institutes of Health

06/09/2003 Reviewer, Lung Biology Pathology Study Section, Center for Scientific Review, National Institutes of Health

10/06/2003 Reviewer, Program Project Grant, NHLBI, NIH

09/23/2004 Reviewer, Program Project Grant, NHLBI, NIH

02/16/2005 Reviewer, Lung Injury, Repair and Remodeling Study Section, Center for Scientific Review, NIH

04/19/2005 Reviewer, CF Center Application, NIDDK, NIH

03/17/2006 Reviewer, Respiratory Sciences SBIR, NIH

06/19/2006 Reviewer, Respiratory Sciences SBIR, NIH

11/08/2006 Reviewer Respiratory Sciences SBIR, NIH

01/10/2007 Reviewer, P30 Center Grants, NIDDK, NIH

03/06/2007 Reviewer, P50 Center Grants, NIEHS, NIH

07/24/2007 Reviewer, University of Michigan GCRC proposal

03/05 & 06/2008 Reviewer, SBIR Small Business: Respiratory Sciences; NIH

06/08 & 07/11 Chair of Review Panel, Program for Clinical Excellence Awards, national Cystic Fiborsis Foundation, Bethesda, MD

09/15/2008 Reviewer, Program Project Grant, NHLBI, NIH

12/16/2008 Reviewer, LIRR and RIBT ad hoc study section, SCR, NIH

07/29/2009 Reviewer, P30 Center Grant, NIDDK, NIH

09/15/2010 Reviewer, Welcome Trust Grant, London, UK

01/25/2011 Reviewer, Pilot projects for P30 Center Grant, NIDDK, NIH for University of Pennsylvania

07/25/2011 Chair of Review Panel, Program for Clinical Excellence Awards, national Cystic Fiborsis Foundation, Bethesda, MD

12/11/2011 Acting Chair and reviewer, Cystic Fibrosis Research and Traslational Core Centers (P30), NIDDK, NIH

07/02/2013 Reviewer, NHLBI R21/R33 applications for RFA “Functional Assays to Screen Genomic Hits”

09/11/2013 Chair of Review Committee, Cystic Fibrosis Foundation Palliative Care Grants, Cystic Fibrosis Foundation, Bethesda, MD

**Teaching**

*National*

1993 Symposium Organizer, "Resolution and Repair of Inflammatory Lung Injury", American Thoracic Society Annual Scientific Meeting

1993, 2006 – present Chairperson, "Adult Clinical Fellows Session", Seventh Annual North American Cystic Fibrosis Conference, Dallas, Texas

1994 Discussion Leader, "Clinical Trial Design for Gene Therapy of CF", Annual North American Cystic Fibrosis Conference, Orlando, FL

1995 Chairperson, "Complications Evolving from Longer Life Spans of Patients with CF", Annual North American Cystic Fibrosis Conference, Dallas, Texas

1996 Work shop organizer, “Overcoming barriers in establishing adult CF centers”, Annual North American Cystic Fibrosis Conference, Orlando, FL

1996 Organizer, Pulmonary Section of Central Society for Clinical Research, Annual Meeting, Chicago, IL

1. Symposium organizer, CF Diagnosis, Annual North American Cystic Fibrosis Conference, Baltimore, MD
2. Short course organizer and speaker, Adult Cystic Fibrosis, Annual North American Cystic Fibrosis Conference, Orlando, FL

2003 Primer on Cystic Fibrosis for Pulmonologists, American Thoracic Society Annual Meeting, Seattle, WA

2003 – present Program Committee, North American Cystic Fibrosis Conference, Bethesda, MD

2004 Short course organizer and speaker, Adult Cystic Fibrosis, Annual North American Cystic Fibrosis Conference, St. Louis, MO

2008 Plenary Speaker, North American Cystic Fibrosis Conference, Orlando, FL.

2011 Featured speaker, Michigan Society for Respiratory Care, Frankenmuth, MI

 *University of Michigan*

1981 – present Attending physician Critical Care Medicine Unit, Pulmonary Ward, Pulmonary/Critical Care Consult Service

1984 - 1992 Pulmonary section coordinator, Introduction to Clinical Sciences-501

1985 - 1992 Pulmonary section instructor, Applications of Dentistry to Medicine-605

1992 – present Lecturer, M2 sequence, Cystic Fibrosis

1993 – 1996 Ph.D. Thesis Advisory Committee, Monica Zepeda, Department of Human Genetics

1994 – 2001 Lecturer, EPID-703, Update in Infectious Diseases

1994 – 1997 Chief's Rounds, Dept. of Internal Medicine ~ 1/month

1994 – 2009 Morning Report, Dept. of Internal Medicine ~ 1 to 4/year

1995 – 2005 Intern's Report, ~1 to 4 / year

2001 Lecturer, Organogenesis of Complex Tissues (CDB 683)

2004 – present Lecturer, Advanced Clinical Concepts in Medical Genetics (HG649); Cystic Fibrosis

2008 – present Lecturer, M2 sequence, Gas exchange and blood gas interpretation

# Committee, Organizational, and Volunteer Services

Institutional

1981 – 1987, Physician liaison, Pulmonary Inpatient Service, University Hospital, 1991 – 1995 Ann Arbor, MI

1981 – 1995 Infection Control Committee, University Hospital

1981 – 1995 Tuberculosis consultant to Infection Control Committee, University Hospital

1982 – 1984;1989–92 Internal Medicine Housestaff Selection Committee

1992 – 1994 Cystic Fibrosis Research Development Program, Executive Committee, University of Pennsylvania

1994 - present Director, Adult Clinical Program, Cystic Fibrosis Foundation Accredited Clinical Center, University of Michigan Medical Center

1995 – 1998 Bed Utilization Committee

1995 – 1997 Senior Operations Council

1995 – 1997 Taubman Center Task Force

1995 – 1997 Teaching Physicians Task Force

1995 – 1996 Internal Medicine Contingency Committee

1995 – 1996 General Medicine Coordinated Steering Committee

1995 – 1997 Practice Management Steering Committee

1995 – 1997 Program for Excellence Committee

1996 – 1998 Faculty Group Practice Board of Directors

1996 – 1998 Faculty Group Practice Incentive Subcommittee

1996 – 1998 Faculty Group Practice Professional Standards Subcommittee

1997 – 1998 Faculty Group Practice Finance Subcommittee

1998 – 2002 Member, Biomedical Research Council, University of Michigan

1999 – 2004 Sabbatical Committee, Department of Internal Medicine

2000 – 2003 Underleider Memorial Award Committee

2001 – 2003 Chair, Data Safety and Monitoring Board, University of Michigan Center for Gene Therapy

2001 Taubman Center Improvement Strategy Committee

2001 – 2004 Member, University of Michigan Medical School Advisory Committee on Appointments, Promotions, and Tenure (ACAPT)

2003 – 2004 Chair, University of Michigan Medical School Advisory Committee on Appointments, Promotions, and Tenure (ACAPT)

2002 Member, Task Force for Curriculum Review Committee, Medical School.

2003 Subcommittee on faculty affairs for LCME re-accreditation, Dean’s Office, University of Michigan Medical Center

2003 – 2007 Medical School Admissions Committee, Applicant interviewer

2004 – present Ad hoc committee for Promotion Review, Office of the Provost, University of Michigan

2006 – present Member, Medical Liability Review Committee, University of Michigan Medical Center

2007 – present Advisor, Promotions Committee, Department of Internal Medicine

2007 – present Advisor, CV Review Committee, Department of Internal Medicine

2077 – present Advisor, Faculty Performance Review Committee, Department of Internal Medicine

2007 – present Sabbatical Committee, Department of Internal Medicine

2008 – 2011 Member, Executive Committee for Clinical Affairs, University of Michigan Health Sciences Center

2008 – 2011 Member, Nominating and Bylaws Committee, Faculty Group Practice, University of Michigan Medical School

2009 – present Member, Advisory Board to the ADVANCE Program, University of Michgan Medical School

2010 – present Member, Advisory Committee for Faculty Development, Dean’s Office, University of Michigan Medical School

2010 Member, Internal Review Committee for Division of Molecular Medicine and Genetics Division; Departmetn of Internal Medicine

2011 – present Member, Search committee, Pulmonary/Critical Care Medicine Division Chief

Regional

1981 – 1999 Michigan Thoracic Society, Executive Committee 1983 - 1991; President 1987 - 1989

1985 - 1991 American College of Chest Physicians, Michigan Chapter, Executive Committee 1983 - 1991; President 1983 - 1989

1987 – 1995 American Lung Association of Michigan, Board member

1987 – 1992, American Lung Association of Michigan, Executive Committee &
 1994 – 1995 member

1987 – 1995 American Lung Association of Michigan, Chairman, Research and Training Committee

1987 – 1997 Central Society for Clinical Research, Councilor 1989-1992, Pulmonary Subspecialty Section, Chair-elect 1993-1995, Chair 1995-97

1990 – 1993 Huron Valley Region of the American Lung Association of Michigan, Council member

1993 – 1995 American Lung Association of Michigan, Member of Ad Hoc Committee on Organizational Priorities

1993 – 1994 Member, Governor's Michigan Chronic Advisory Committee, Michigan Department of Public Health. Chairperson of the Pulmonary Disease Subcommittee.

National

1984 – 1988 Cecile Lehman Mayer Research Award, American College Chest Physicians (Awards Committee)

1995 – 2002 Cystic Fibrosis Foundation; National Center Committee member

2000 – 2002 Adult Program Directors Representative, Cystic Fibrosis Foundation, Bethesda, MD

2001 – 2005 Member, National Quality Improvement Advisory Committee, Cystic Fibrosis Foundation, Bethesda, MD

2001 – 2002 Member, Consensus Conference on Infection Control, Cystic Fibrosis Foundation, Bethesda, MD

2001 – present Associate Chair, Data Safety Monitoring Board, Cystic Fibrosis Foundation, Bethesda, MD

2001 – present Program Committee, Annual North American Cystic Fibrosis, Bethesda, MD

2002 – present Medical Advisory Council, National Cystic Fibrosis Foundation,
 Bethesda, MD

2003 Chair, Annual North America Cystic Fibrosis Conference, Anaheim, CA

2006 – 2009 Chair, Adult Clinical Care Committee, National Cystic Fibrosis Foundation

2009 -- present Chair, Clinical Section, Program Committee, North American Cystic Fibrosis Conference, Minneapolis, MN

2009 – present Member, Clinical Research Executive Committee, Therapeutic Development Network, Cystic Fibrosis Foundation, Bethesda, MD

2011 – present Member, Medical Advisory Committee, Cystinosis Research Network

2010 – present Member, Chronic Disease Treatment Guidelines Committee, national Cystic Fibrosis Foundation, Bethesda, MD

2013 – present Member, Cystinosis Research Network Scientific Advisory Committee, Washington, DC

# Consulting Positions

1991 – 1992 Biogen; Cambridge, MA

1993 – 1994 NHLBI Task Force on Research in Cardiopulmonary Dysfunction in Critical Care Medicine

1993 – 1994 Centers for Disease Control on Hantavirus/lung disease outbreak in Four Corners area

1993 – 1996 Tuberculosis in primates and large mammals; Detroit Zoological Park

1994 – 2000 External Advisory Committee, Gene Therapy for Cystic Fibrosis and Genetic Diseases Center, University of Pennsylvania, Philadelphia, PA

1997 Centers for Disease Control on Hantavirus Pulmonary Disease, CDC, Atlanta, GA

2006 Novartis, Advisory Committee on Xolair in Cystic Fibrosis-Related Allergic Bronchopulmonary Aspergillosis, Denver, CO

2010 NanoBio, ad hoc advisory committee, Ann Arbor, MI

2013 Jannsen Pharmaceuticals, data safety monitoring committee member

# Visiting Professorships, Seminars, and Extramural Invited Presentations

1990 9th Annual Big Sky Pulmonary Conference: "Asthma Management", "ARDS" Big Sky, MT

1990 Grand Rounds, Flint Osteopathic Hospital, "Prevention of Clinical Tuberculosis", Flint, MI

1991 Grand Rounds, Northern Michigan Hospitals, "Tuberculosis in the 90's", Traverse City, MI

1991 Grand Rounds, Pulmonary Medicine Division, Wayne State University, "Repair of Inflammatory Lung Injury", Detroit, MI

1991 National Marfan Foundation's 7th Annual Conference, "Spontaneous Pneumothorax in Marfan Syndrome", Ann Arbor, MI

1991 Cystic Fibrosis Conference, Children's Hospital of Michigan, "Adult Care Issues in Cystic Fibrosis", Detroit, MI

1991 Michigan Society for Respiratory Care Annual Conference, "Management of Acute Asthma", Gaylord, MI

1992 11th Annual Big Sky Pulmonary Conference, "Cystic Fibrosis in the Adult", "ARDS", "Tuberculosis Update", Big Sky, MT

1993 Drug Information Association's 29th Annual Meeting, "Gene Therapy for Cystic Fibrosis", Chicago, IL

1993 "Fibrinolysis in Inflammatory Lung Injury", University of Toronto, Toronto, Ontario, Canada

1993 "Gene Therapy for Cystic Fibrosis", Medical Grand Rounds, St. Michael's Hospital, Toronto, Ontario, Canada

1993 "Clinical Protocol for Cystic Fibrosis Gene Therapy", University of Pennsylvania, Philadelphia, PA

1993 "Prevention of Spread of Tuberculosis", Detroit Zoological Park, Detroit, MI

1993 "Fibrinolysis as a Mediator of Inflammatory Repair", American Thoracic Society Annual Scientific Meeting, San Francisco, CA

1993 "Gene Therapy for Cystic Fibrosis", Twenty-Ninth Annual Meeting, Drug Information Association, Chicago, IL

1993 "Alveolar Epithelium in Inflammatory Injury", Nancy Weller Memorial Lecture, Case Western Reserve University, Cleveland, OH

1993 "Pulmonary Alveolar Epithelial Cells: The Alveolar Wall Flower Comes of Age", Mini-Sate-of-the-Art Lecture, Annual meeting of the Central Society for Clinical Research, Chicago, IL

1994 "Gene Therapy for Cystic Fibrosis: Current Progress and Future Challenges", Annual Meeting of the American Thoracic Society, Boston, MA

1994 "Clinical Year in Review, Cystic Fibrosis", Annual Meeting of the American Thoracic Society, Boston, MA

1994 "Impact of Molecular Biology on the Current Management of Cystic Fibrosis", Indiana Thoracic Society, Indianapolis, IN.

1994 Chair of break-out session on phase I trials for gene therapy in cystic fibrosis, Williamsburg Conference, Workshop on Gene Therapy in CF, Williamsburg, VA

1994 Roundtable discussion leader, "Clinical Trial Design for Gene Therapy of CF", Eight Annual North American Cystic Fibrosis Conference, Orlando, FL

1994 Visiting Professor, The Hospital for Sick Children, Toronto, Canada; presentation: "Role of Fibrin Removal in Lung Repair".

1994 Visiting Professor, Thrombosis Research Center, Henderson Hospital, Hamilton, Ontario; presentation: "Fibrin Formation and Clearance in the Alveolar Space".

1994 36th Annual Respiratory Care Symposium, "New Therapies for Cystic Fibrosis", Grand Rapids, MI

1994 1994 Michigan Veterinary Conference, "Tuberculosis and AIDS: A Deadly Combination", Lansing, MI

1996 Visiting Professor, Institute for Environmental Health, University of Pennsylvania: “The Role of Fibrinolysis in Pulmonary Fibrosis”.

1996 Workshop organizer and presenter, “Overcoming Barriers to Setting up Adult CF Programs”, Annual North American Meeting of the Cystic Fibrosis Foundation, Orlando, FL

1997 Guest speaker, “Update on Adult Cystic Fibrosis”, Annual meeting of the American Society of Physical Therapists, Dallas, TX

1997 Allen B. Cohen Memorial Lecturer, “Advances in Understanding and Treating Cystic Fibrosis”, Annual Meeting of the Texas Thoracic Society, Austin, TX.

1997 Invited participant, Williamsburg Conference on Gene Therapy for Cystic Fibrosis, Williamsburg, VA.

1997 Speaker, “Gene Transfer of Fibrinolytic Genes to Limit Pulmonary Fibrosis”, Annual Meeting of the Texas Thoracic Society, Austin, TX.

1997 Roundtable Moderator, “Development of Adult CF Programs”, North American Cystic Fibrosis Conference, Nashville, TN

1998 Visiting Professor, University of Texas Southwestern, “Fibrinolytic Gene Transfer for Fibrotic Lung Disease”, Dallas, TX.

1. Symposium moderator, “Vecterology and Host Response”, American Thoracic Society Annual Scientific Meeting, Chicago, IL

1998 Michigan Society for Respiratory Care, "Update on Cystic Fibrosis", Lansing, MI

1998 Roundtable Moderator, “Develoment of Adult CF Programs, North American Cystic Fibrosis Conference, Montreal, Canada

1999 Speaker, Williamsburg Conference on Gene Therapy for Cystic Fibrosis, Williamsburg, VA.

1999 Speaker, "Building the financial and political framework for establishing an adult CF program, North American Cystic Fibrosis Scientific Meeting, Seattle, WA

1999 Moderator, Pulmonary Consultation Session, North American Cystic Fibrosis Scientific Meeting, Seattle, WA

1999 Speaker, University of Iowa guest speaker. “Upregulating fibrinolytic activity to limit pulmonary fibrosis”, Iowa City, Iowa

2002 Speaker, “Fibrinolytic Treatment for Pulmonary Fibrosis”, Notre Dame University, South Bend, IN

2000 Speaker, "Building the financial and political framework for establishing an adult CF program, North American Cystic Fibrosis Scientific Meeting, Baltimore, MD

2000 Moderator, “Diagnostic Issues”, North American Cystic Fibrosis Scientific Meeting, Baltimore, MD

2001 Speaker, Internal Medicine Grand Rounds, Indiana University, Indianapolis, IN

2001 Course organizer, North American Cystic Fibrosis Conference, Orlando, FL

2002 Invited speaker, “The plasminogen activation system in pulmonary fibrosis”, Thrombosis and Fibrinolysis Gordon Conference, Ventura, CA

2003 Internal Medicine Grand Rounds, St. Vincent Hospital, Toledo, OH

2004 Visiting Professor, Justus-Liebig-Universität, Gießen, Germany

2004 Visiting Professor, University of Calgary, Alberta, Canada

2004 Pediatric Grand Rounds, St. Louis University, St. Louis, MO

2005 Speaker, “Early Termination of a Phase II Trial Due to Serious Adverse Events”, Data Safety Monitoring Board, Therapeutic Development Network, Cystic Fibrosis Foundation, Dallas-Fort Worth, TX

2007 Speaker, National CF DSMB meeting, Timpe, Az

2007 Speaker, Dealing with Success: Transition Strategies To Adult Care For Cystic Fibrosis Patients, American Thoracic Society meeting, San Francisco, CA

2008 Plenary Speaker, “Taking the CF Battle to the Extremes: Healthy Starts with Newborn Screening, Healthy Aging with Improved CF Care. North American Cystic Fibrosis Conference, Orlando, FL.

2011 Featured Speaker, Cystic Fibrosis, Michigan Society for Respiratory Care, Frankenmuth, MI

2011 Speaker, Physician Grand Rounds, North American Cystic Fibrosis Conference, Anaheim, CA

**BIBLIOGRAPHY**

*Peer-Reviewed Publications*

1. Reynolds JA, Simon RH. The interaction of polypeptide components of human high density lipoprotein with sodium dodecyl sulfate. J Biol Chem 1974; 249:3937-3940.

2. Camerini-Otero RD, Sollner-Webb B, Simon RH, Williamson P, Zasloff M, Felsenfeld G. Nucleosome structure, DNA folding, and gene activity. Cold Spring Harbor Symp Quant Biol 1978; 42 Pt 1:57-75.

3. Simon RH, Camerini-Otero RD, Felsenfeld G. An octamer of histones H3 and H4 forms a compact complex with DNA of nucleosome size. Nucleic Acids Res 1978; 5:4805-4818.

4. Simon RH, Felsenfeld G. A new procedure for purifying histone pairs H2A+H2B and H3+H4 from chromatin using hydroxylapatite. Nucleic Acids Res 1979; 6:689-696.

5. Simon RH, Scoggin CH, Patterson D. Hydrogen peroxide causes the fatal injury to human fibroblasts exposed to oxygen radicals. J Biol Chem 1981; 256:7181-7186.

6. Grum CM, Simon RH, Dantzker DR, Fox IH. Evidence for ATP degradation in critically ill patients. Chest 1985; 88:763-767.

7. Baldwin SR, Simon RH, Boxer LA, Till GO, Kunkel RG. Attenuation by 2,3-dihy­droxybenzoic acid of cobra venom factor-induced lung injury in the rat. Am Rev Respir Dis 1985; 132:1288-1293.

8. Baldwin SR, Simon RH, Grum CM, Ketai LH, Boxer LA, Devall LJ. Oxidant activ­ity in expired breath of patients with adult respiratory distress syndrome. Lancet 1986; 1:11-14.

9. Simon RH, McCoy JP, Chu AE, DeHart PD, Goldstein IJ. Binding of *Griffonia simplicifolia* I lectin to rat pulmonary alveolar macrophages: Its use in purify­ing type II alveolar epithelial cells. Biochim Biophys Acta 1986; 885:24-42.

10. Laufe MD, Simon RH, Flint A, Keller JB. Adult respiratory distress syndrome in neutropenic patients. Am J Med 1986; 80:1022-1026.

11. Simon RH, DeHart PD, Todd RF III. Neutrophil-induced injury of rat pulmonary alveolar epithelial cells. J Clin Invest 1986; 78:1375-1386.

12. Grum CM, Ragsdale RA, Ketai LH, Simon RH. Plasma xanthine oxidase activity in patients with ARDS. J Crit Care 1987; 2:22-26.

13. Guice KS, Oldham KT, Wolfe RR, Simon RH. Lung injury in acute pancreatitis: Primary inhibition of pulmonary phospholipid synthesis. Am J Surg 1987; 153:54-61.

14. Ketai LH, Simon RH, Kreit J, Grum CM. Plasma hypoxanthine and exercise. Am Rev Respir Dis 1987; 136:98-101.

15. Simon RH. Predictors of adult respiratory distress syndrome. J Crit Care 1987; 2:81-85.

16. Gannon DE, Varani J, Ward WH, Kaplan J, Till GO, Simon RH, Ryan US, Ward PA. Source of iron in neutrophil-mediated killing of endothelial cells. Lab In­vest 1987; 57:37-44.

17. King T, Simon RH. Pulse oximetry for tapering supplemental oxygen in hospital­ized patients. Chest 1987; 92:713-716.

18. Sporn PHS, Simon RH, Peters-Golden M. Hydrogen peroxide-induced arachi­donic acid metabolism in the rat alveolar macrophage. Am Rev Respir Dis 1988; 137:49-56.

19. Chauncey J, Peters-Golden M, Simon RH. Arachidonic acid metabolism by rat alveolar epithelial cells. Lab Invest 1988; 58:133-140.

20. Crim C, Simon RH. Effects of oxygen metabolites on rat alveolar type II cell via­bility and surfactant metabolism. Lab Invest 1988; 58:428-437.

21. Chauncey JB, Simon RH, Peters-Golden P. Rat alveolar macrophages synthesize leukotriene B4 and 12-hydroxyeicosatraenoic acid from alveolar epithelial cell-derived arachidonic acid. Am Rev Respir Dis 1988; 138:928-935.

22. Viscardi RM, Weinhold PA, Beals TM, Simon RH. Cytidylyltransferase enzyme activity in fetal rat lung cells: Activity and subcellular distribution in response to dexamethasone, triiodothyronine, and fibroblast conditioned medium. Exp Lung Res 1989; 15:223-237.

23. Warren JS, Kunkel RG, Simon RH, Johnson KJ, Ward PA. Ultrastructural cytochemical analysis of oxygen radical-mediated Immunoglobulin A immune complex induced lung injury in the rat. Lab Invest 1989; 60:651-658.

24. Simon RH, DeHart PD, Nadeau DM. Resistance of rat pulmonary alveolar ep­ithelial cells to neutrophil- and oxidant-induced injury. Am J Respir Cell Mol Biol 1989; 1:221-229.

25. Shlafer M, Brosamer K, Forder JR, Simon RH, Ward PA. Grum CM. Cerium chlo­ride as a histological marker of oxidants in reperfused ischemic hearts. J Mol Cell Cardiol 1990; 22:83-97.

26. Lipchik RJ, Chauncey RB, Paine R, Simon RH, Peters-Golden M. Arachidonate metabolism increased as rat alveolar type II cells differentiate *in vitro*. Am J Physiol 1990; 3:L73-L80.

27. Gross TJ, Simon RH, Sitrin RG. Expression of urokinase-type plasminogen activator by rat pulmonary alveolar epithelial cells. Am J Respir Cell Mol Biol 1990; 3:449-456.

28. Simon RH, Edwards JA, Reza MM, Kunkel RG. Injury of rat pulmonary alveolar epithelial cells by H2O2: dependence on phenotype and catalase. Am J Physiol 1991; 260:L318-L325.

29. Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase. Am J Physiol 1990; 260: L286-L295.

30. Simon RH, Gross TJ, Edwards JA, Sitrin RG. Fibrin degradation by rat pulmonary alveolar epithelial cells. Am J Physiol 1992; 262:L482-L488.

31. Gross TJ, Simon RH, Sitrin RG. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 6:397-403.

32. Christensen PJ, Kim S, Simon RH, Toews GB, Paine R III. Differentiation-related expression of ICAM-1 by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1993; 8:9-15.

33. Simon RH, Scott MJ, Reza MM, Killen PD. Type IV collagen production by rat pulmonary alveolar epithelial cells. Am J Respir Cell Mol Biol 1993; 8:640-646.

34. Mody CH, Paine R, Shahrabadi S, Simon RH, Pearlman E, Eisenstein BI, Toews GB. Legionella pneumophila replicates within rat alveolar epithelial cells. J Infect Dis 1993; 167:1138-1145.

35. Engelhardt JF, Simon RH, Yang Y, Zepeda M, Weber-Pendleton S, Doranz B, Grossman M, Wilson JM. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Biological efficacy study. Human Gene Therapy 1993;4:759-769.

36. Simon RH, Engelhardt JF, Yang Y, Zepeda M, Weber-Pendleton S, Grossman M, Wilson JM. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study. Human Gene Therapy 1993;4;771-780.

37. Wilson JM, Engelhardt JF, Yang Y, Simon RH, Baker JR, Grossman M, Collins FS. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: A phase I trial. Human Gene Therapy 1994; 5:501-519.

38. Paine R III, Christensen P, Toews GB, Simon RH. Regulation of ICAM-1 expression by extracellular matrix, cell shape and cell-cell interactions in primary cultures of rat pulmonary alveolar epithelial cells. Am J Physiol 1994; 266:L476-L484.

39. Simon RH, Paine R III. Participation of pulmonary alveolar epithelial cells in lung inflammation. J Lab Clin Med 1995; 126:108-118.

40. McCoy RD, Davidson BL, Roessler BL, Huffnagle GB, Janich SL, Laing TJ, Simon RH. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995; 6:1553-1560.

41. McCoy RD, Davidson BL, Roessler BJ, Huffnagle GB, Simon RH. Expression of human interleukin-1 receptor antagonist in mouse lungs using a recombinant adenovirus: Effects on vector-induced inflammation. Gene Therapy 1995; 2:437-442.

42. Eitzman DT, McCoy RD, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97:232-237.

43. Paine R and Simon RH. Expanding the frontiers of lung biology through the creative use of pulmonary alveolar epithelial cells in culture. Am J Physiol 1996; 270:L484-486.

44. Hattori N, Sisson TH, Xu Y, Simon RH. Upregulation of fibrinolysis by adenovirus-mediated transfer of urokinase-type plasminogen activator genes to lung cells in vitro and in vivo. Hum Gene Ther 1999; 10:215-222.

1. Hattori N, Sisson T, Xu Y, Desai TJ, Simon RH. Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung. Am J Physiol: Lung 1999; 277:L573-L579.
2. Sisson TH, Hattori N, Xu Y. Simon RH. Adenovirus-mediated gene transfer of urokinase plasminogen activator to upregulate fibrinolysis in the murine model of bleomycin-induced pulmonary fibrosis. Hum Gene Ther 1999; 10:2315-23.
3. Swaisgood CM, French. EL, Noga C. Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000; 157:177-187.
4. Noone, PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan M, Simon RH, Silverman LM, Knowles MR. Lung Disease Associated with the IVS8 5T Allele of the CFTR Gene. Am. J. Respir. Crit. Care Med. 2000; 162:1919-1924
5. Hattori H, Degen JL, Sisson TH, Liu H, Moore BB, Randrangi RG, Simon RH, Drew AF. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106:1341-1350.
6. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH. Inducible lung specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2002; 283:L1023-L1032.
7. Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, Travis WD, Martinez FJ, Murray S, Simon RH. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003; 9:52-56.
8. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NH, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003; 163:445-52.
9. Yankaskas JR, Marshall BC, Suffian B, Simon RH, Rodman D. Cystic fibrosis adult care – Consensus Conference Report. Chest 2004; 125: 1S-39S.
10. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, Simon RH, Nakamura T, Miyake M. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004; 164:0191-8.
11. Sisson TH, Simon RH. Cell specific control of coagulation and fibrinolysis in the lung. Thromb Haemost 2004; 92:435-7.
12. Nishiuma T, Sisson TH, Subbotina N, Simon RH. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol, 2004; 31:552-8.
13. Lazar MH, Christensen PJ, Yu B, Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH, Sisson TH. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 2004; 31:672-8.
14. Sisson TH, Hansen JM, Shah M, Du M, Ling T, Simon RH, Christensen PJ. Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. Am J Resp Cell Mol Biol 2006; 34:552-560.
15. Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am J Resp Cell Mol Biol 2006;35:705-13.
16. Sisson TH, Simon RH. The plasminogen activation system in lung disease. Curr Drug Targets 2007;8:1016-29.
17. Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Resp Cell Mol Biol 2008;38:78-87.
18. Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol:Lung 2009;296:L337-46.
19. Sisson TH, Nguyen M-H, Yu B, Simon RH, Koh TJ. Urokinase-type plasminogen activator increased hepatocyte growth factor activity required for skeletal muscle regeneration. Blood 2009;114:5052-61.
20. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH. Targeted injury of type II alveolar epithelial cells induced pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:254-63.
21. Bauman KA, Wettlaufer SH, Okunishi K, Vannella KM, Stoolman JS, Huang SK, Courey AJ, White ES, Hogaboam CM, Simon RH, Toews GB, Sisson TH, Moore BB, Peters-Golden M. Anti-fibrotic actions of plasminogen activation are mediated via upregulation of prostaglandin E2 synthesis. J Clin Invest 2010;120;1950-60.
22. Courey AJ, Horowitz JC, Kim KK, Koh TJ, Novak ML, Subbotina N, Warnock M, Xue B, Cunningham AK, Lin Y, Goldklang MP, Simon RH, Lawrence DA, Sisson TH. The vitronectin binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011;118:2313-21.
23. Okunishi K, Sisson TH, Huang SK, Hogaboam CM, Simon RH, Peters-Golden M. Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem. 2011;286:32231-43.
24. Osterholzer JJ, Christensen PJ, Lama V, Horowitz JC, Hattori N, Subbotina N, Cunningham A, Lin Y, Murdock BJ, Morey RE, Olszewski MA, Lawrence DA, Simon RH, Sisson TH. PAI-1 Promotes the Accumulation of Exudate Macrophages and Worsens Pulmonary Fibrosis Following Type II Alveolar Epithelial Cell Injury. J Pathol. 2012;228(2):170-80.
25. Osterholzer JJ, Olszewski MA, Murdock BJ, Chen GH, Erb-Downward JR, Subbotina N, Browning K, Lin Y, Morey RE, Dayrit JK, Horowitz JC, Simon RH, Sisson TH. Implicating Exudate Macrophages and Ly-6Chigh Monocytes in CCR2-Dependent Lung Fibrosis following Gene-Targeted Alveolar Injury. J Immunol. 2013;190:3447-57

*Non Peer-Reviewed Publications*

1. Martinez FJ, Simon RH. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Current Pharmaceutical Design. 2004; 10:3095-3110.

2. Simon RH, McCoy K, Retsch-Bogart GZ. Emerging insights on the future of cystic fibrosis management: Improving lung function and managing infections. Monograph accompanying a France Foundation organized symposium held at the North American Cystic Fibrosis Conference, Anaheim, CA Oct. 2007.

*Chapters in Books*

1. Simon RH. Mediastinal Diseases. In Mitchell RS, Petty TL, eds. Synopsis of Clinical Pulmonary Disease, 3rd Edition. (St. Louis: CV Mosby 1982), 280-287.

2. Simon RH. Pathophysiology and etiology of the adult respiratory distress syndrome. In Dantzker DR, ed. Critical Care and Pulmonary Medicine. (Orlando, FL: Grune & Stratton, Inc. 1986), 1-24.

3. Simon RH, Ward PA. Adult respiratory distress syndrome. In Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. (New York: Raven Press 1988), 815-827.

4. Simon RH. Pathophysiology and etiology of the adult respiratory distress syndrome. In Dantzker DR, ed. Critical Care and Pulmonary Medicine, 2nd Edition. (Orlando, FL: W.B. Saunders 1991), 3-24.

5. Simon RH. The biology and biochemistry of pulmonary alveolar epithelial cells. In Parent, RA, ed. A Comprehensive Treatise on Pulmonary Biology, Vol. 1. Comparative Biology of the Normal Lung. (Boca Raton: CRC Press 1992), 545-564.

6. Simon RH, Ward PA. Adult respiratory distress syndrome. In Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd Edition. (New York: Raven Press 1992), 999-1016.

7. Simon RH. Pulmonary alveolar epithelial cells in pulmonary fibrosis. Phan SH, Thrall RS, volume eds. Pulmonary Fibrosis. Lenfant C, series ed. Lung Biology in Health and Disease. Vol. 80. (Marcel Dekker, Inc. 1995), 511-540.

8. Simon RH. Pathogenesis of acute lung injury. In Dantzker DR, Scharf, SM eds. Cardiopulmonary Critical Care. 3rd Edition. (Philadelphia, PA: W.B. Saunders 1998), 3-27.

9. Sisson TH, Simon RH. The use of *in vivo* gene transfer to study pulmonary fibrosis. In: SM Albelda (vol. ed.) Gene Therapy in Lung Disease, C Lenfant (series ed.) Lung Biology in Health and Disease, Marcel Dekker, Inc. 2002, 219-230.

10. Simon RH. Gene Therapy for Cystic Fibrosis. In Rose BD, ed. UptoDate in Medicine. 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010.

11. Simon RH. Treatment of the Pulmonary Disease in Cystic Fibrosis. In Rose BD, ed. UptoDate in Medicine. 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010.

12. Simon RH. Cystic fibrosis: Overview of the treatment of lung disease. In Rose BD, ed. UptoDate in Medicine. 2010, 2011, 2012, 2013

13. Simon RH. Cystic fibrosis: Antibiotic therapy for lung disease. In Rose BD, ed. UptoDate in Medicine. 2010, 2011, 2012, 2013.

14. Simon RH, Sisson TH. Cystic fibrosis: Investigational therapies. In Rose BD, ed. UptoDate in Medicine, 2010, 2011, 2012, 2013.

*Abstracts, Preliminary Communications, Panel Discussions*

1. Camerini-Otero RD, Simon RH, Felsenfeld G. Nucleosome and nucleosome vari­ants. Biophys J 1978; 21:95a.

2. Simon RH, Scoggin CH, Patterson D. Hydrogen peroxide mediates the toxic ef­fect of oxygen radicals on human fibroblasts. Chest 80 (Suppl) 1981; 45S.

3. Grum CM, Dantzker DR, Fox IH, Simon RH. Elevated levels of plasma hypoxan­thine and xanthine in critically ill patients. Am Rev Respir Dis 1983; 127:99A.

4. Grum CM, Dantzker DR, Fox IH, Simon RH. Purine nucleotide degradation products in the plasma of critically ill patients. Clin Res 1983; 31:257A.

5. Crim C, Simon RH. Oxygen metabolites impair palmitate incorporation into disaturated phosphatidylcholine. Clin Res 1984; 32:427A.

6. Crim C, DeHart PD, Simon RH. Stimulated neutrophils impair palmitate incor­poration into desaturated phosphatidylcholine by rat type II pneumocytes. Am Rev Respir Dis 1984; 129:A325.

7. Laufe MD, Flint A, Simon RH. Failure of neutropenia to protect the lung against the development of ARDS in humans. Am Rev Respir Dis 1984; 129:A112.

8. Baldwin SR, Boxer LA, Till GO, Simon RH. Prevention of complement and neu­trophil mediated acute lung injury in the rat using 2,3-dihydroxybenzoic acid. Am Rev Respir Dis 1984; 129:A103.

9. Crim C, Simon RH. Reactive oxygen metabolites injure rat type II cells and im­pair palmitate incorporation into disaturated phosphatidylcholine. Clin Res 1984; 32:427A.

10. Simon RH, Watts WJ. Differentiation of rat type II pneumocytes into squamous-like epithelial cells increases their susceptibility to neutrophil-induced damage. Clin Res 1984; 32:437A.

11. Baldwin SR, Devall LJ, Simon RH, Grum CM, Ketai LH, Boxer LA. Oxidant activ­ity in expired breath and neutrophil activation in patients with the adult respi­ratory distress syndrome. Clin Res 1985; 33:462A.

12. Simon RH, McCoy JP Jr, Chu AE, DeHart PD, Goldstein IJ. Isolation procedure for type II pneumocytes using *Griffonia simplicifolia* I lectin. Am Rev Respir Dis 1985; 131:A307.

13. Baldwin SR, Devall LJ, Simon RH, Grum CM, Ketai LH, Boxer LA. Oxidant activ­ity in expired breath from patients with adult respiratory distress syndrome. Am Rev Respir Dis 1985; 131:A136.

14. Albertson RD III, Simon RH, Phan SH. Production of a fibroblast proliferation factor by isolated rat type II pneumocytes. Am Rev Respir Dis 1985; 131:A361.

15. Viscardi RM, Simon RH, Weinhold P. Hormonal regulation of choline phos­phate cytidylyltransferase in fetal rat alveolar type II cells. Pediatr Res 1985; 19:164A.

16. Viscardi RM, Simon RH, Weinhold PA. Fibroblast pneumocyte factors: Re­sponse of fetal and adult alveolar type II cells. Pediatr Res 1986; 20:198A.

17. Chauncey JB, Simon RH, Peters-Golden M. Arachidonic acid metabolism in rat alveolar type II cell cultures. Am Rev Respir Dis 1986; 133:A293.

18. Gannon DE, Varani J, Till GO, Ryan US, Simon RH, Ward PA. Source of iron in neutrophil-mediated killing of endothelial cells. Am Rev Respir Dis 1986; 133:A262.

19. Ragsdale RA, Grum CM, Ketai LH, Simon RH. Plasma xanthine oxidase activity in adult respiratory distress syndrome. Am Rev Respir Dis 1986; 133:A21.

20. Simon RH, DeHart PD, Todd RF, Curnutte JT. Oxidant-independent killing of alveolar epithelial cells by stimulated neutrophils. Am Rev Respir Dis 1986; 133:A274.

21. Chauncey JB, Simon RH, Peters-Golden ML. Alveolar macrophage LTB4 produc­tion from type II cell derived arachidonate. Am Rev Respir Dis 1987; 135:A344.

22. Gannon DE, Varani J, Phan SH, Ward JH, Simon RH, Ryan US, Ward PA. Action of deferoxamine mesylate in protecting endothelial cells from neutrophil in­duced cytotoxicity. Am Rev Respir Dis 1987; 135:A102.

23. Shlafer M, Brosamer K, Kunkel RG, Simon RH, Ward PA, Grum CM. Electron microscopic-histochemical demonstration of hydrogen peroxide at endothe­lium of isolated ischemic-perfusion hearts. Circulation 1987; IV-535.

24. Simon RH, DeHart PD, Nadeau D. Role of glutathione-dependent reactions in protecting alveolar epithelial cells from oxidant- and neutrophil-induced in­jury. Am Rev Respir Dis 1988; 137:A79.

25. Chauncey JB, Simon RH, Peters-Golden ML. Alveolar epithelial cell production of 6-keto-prostaglandin F1a is diminished in the presence of alveolar macro­phages. Am Rev Respir Dis 1988; 137:A88.

26. Lipchik RH, Chauncey J, Paine R, Simon RH, Peters-Golden M. Arachidonic acid release and metabolism is augmented as rat type II alveolar epithelial cells alter their phenotype in culture. Am Rev Respir Dis 1989; 139:A406.

27. Simon RH, DeHart PD, Edwards JA. Isolated rat alveolar type II cells become more susceptible to oxidant-induced injury as they alter their state of differentiation with time in culture. Am Rev Respir Dis 1989; 139:A402.

28. Mody CH, Paine R, Simon R, Toews GB. Legionella pneumophila replicates in alveolar type II cells. Clin Res 1989; 37:480A.

29. Lipchik RJ, Chauncey J, Simon RH, Peters-Golden M. Cyclooxygenase activity is augmented as rat type II alveolar epithelial cells differentiate in culture. Clin Res 1989; 37:919A

30. Peters-Golden M, Chauncey J, Coburn K, Lipchik R, Simon R. Protein kinase C-activated arachidonic acid metabolism increases as type II alveolar epithelial cells differentiate *in* *vitro*. Am Rev Respir Dis 1990; 141:A89.

31. Gross RJ, Simon RH, Sitrin RG. Urokinase-type plasminogen activator expression by rat pulmonary alveolar epithelial cells. Am Rev Respir Dis 1990; 141:A357.

32. Lipchik RJ, Simon RH, Paine R, Peters-Golden M. Changes in cyclooxygenase as rat type II alveolar epithelial cells differentiate in culture. Am Rev Respir Dis 1990; 141:A633.

33. Kahn LL, Simon RH, Ryan US, Varani J, Morganroth ML. Hypoxia-reoxygenation does not injure endothelial cells or affect PMN adherence. Am Rev Respir Dis 1990; Am Rev Respir Dis 1990; 141:A161.

34. Gross TJ, Edwards JA, Sitrin RG, Simon RH. Rat alveolar epithelial cells mediate plasmin-dependent lysis of plasma clots. Clin Res 1990; 38:873A.

35. Gross TJ, Simon RH, Kelly CJ, Sitrin RG. Alveolar epithelium-mediated plasminogen activation: Concomitant expression of urokinase and plasminogen activator inhibitor-1. Clin Res 1990; 38:824A.

36. Scott MJ, Reza MM, Killen P, Simon RH. Type IV collagen gene expression in rat pulmonary alveolar epithelial cells. Am Rev Respir Dis 1991; 143:A301.

37. Simon RH, Gross TJ, Edwards JA, Sitrin RG. Clearance of fibrin by rat pulmonary alveolar epithelial cells. Am Rev Respir Dis 1991; 143:A301.

38. Gross TJ, Simon RH, Sitrin RG. Tissue factor expression by rat pulmonary alveolar epithelial cells. Clin Res 1991; 39: 332A.

39. Simon RH, Garni-Wagner BA, Edwards JA, Sitrin RG, Todd RF III. Expression of human urokinase-type plasminogen activator receptor augments fibrinolytic activity of murine 3T3 cells. Fourth International Workshop on Molecular and Cellular Biology of Plasminogen Activation. Cold Spring Harbor Laboratory. 1993.

40. Paine R III, Christensen PJ, Toews GB, Simon RH. Regulation of ICAM-1 expression by cellular spatial interactions in primary cultures of rat alveolar epithelial cells. Clin Res 1993; 41:673A.

41. Engelhardt J, Simon R, Zepeda M, Yang Y, Wilson JM. Safety and efficacy of recombinant adenoviruses for lung directed gene therapy in nonhuman primates. Ped Pulmon 1993; Suppl. 9; 184.

42. McCoy RD, Davidson BL, Roessler BJ, Strieter RM, Simon RH. *In vivo* expression of human interleukin-1 receptor antagonist in mouse lung using an adenoviral vector. Am J Respir Crit Care Med 1994; 149:A237.

43. McCoy RD, Davidson BL, Roessler BJ, Simon RH. Pulmonary inflammation induced by adenovirus-based gene therapy vectors is caused in part by the vector particle itself. Am J Respir Crit Care Med 1995; 151:A671.

44. McCoy RD, Eitzman DT, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. Am J Respir Crit Care Med 1995; 151:A51.

45. Simon RH, Edwards JA, Sitrin RG. Fibrin is rapidly formed and lysed when plasma is introduced into the alveolar space of intact lungs. Am J Respir Crit Care Med 1995; 151:A344.

46. Simon RH, McCoy RD, Roskoph CH, Roessler BJ, Hattori N, Sisson TH. Transfer of a urokinase-type plasminogen activator gene to alveolar epithelial cells accelerates degradation of overlying fibrin matrices. Am J Respir Crit Care Med 1997; 155:A461.

47. Simon RH, Hattori N, Sisson TH. Adenovirus-mediated transfer of urokinase-type plasminogen activator genes to the lungs of mice upregulates plasminogen activator activity. Fibrinolysis Proteolysis 1997; 11(Suppl 3):53.

48. Hattori N, Desai T, Sisson TH, Simon RH. Transfer of the urokinase-type plasminogen activator gene to pulmonary epithelium upregulates fibrinolytic activity predominantly at the cellular surface. Am J Respir Crit Care Med 1998; 157:A566.

1. Sisson TH, Hattori N, Simon RH. Adenovirus-mediated gene transfer of urokinase plasminogen activator to upregulate fibrinolysis in the murine model of bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:A566.
2. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced lung fibrosis by upregulating alveolar fibrinolysis through adenovirus-mediated transfer of urokinase-type plasminogen activator genes. Am Soc Gene Ther, 1999.
3. Hattori H, Sisson TH, Simon RH. Urokinase-type plasminogen activator bound to its receptor augments fibrinolysis on epithelial cells and in the lung. Am J Respir Crit Care Med 1999; 159:A189.
4. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced lung fibrosis by upregulating alveolar fibrinolysis through adenovirus-mediated transfer of urokinase-type plasminogen activator genes. Am J Respir Crit Care Med 1999; 159:A239.
5. Pandrangi R, Hattori N, Sisson T, Simon R, Standiford T, Toews G, Huffnagle G. Construction and determination of efficacy of adenoviral vector-mediated expression of GM-CSF. Fourth International Conference on Cryptococcus and Cryptococcosis (1999), London, UK.
6. Sisson TH, Patwardhan AA, Hattori N, Simon RH. Development of a transgenic model to study the role of urokinase-type plasminogen activator in pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163:A715.
7. Lazar MH, Hanson KE, Simon RH, Sisson TH. Plasminogen activator inhibitor-1 deficiency limits fluorescein isothiocyanate-induced pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:A167.
8. Sisson TH, Patwardhan AA, Hanson KE, King M, Simon RH. Upregulation of lung urokinase expression leads to improved survival following a bleomycin-induced lung injury. Am J Respir Crit Care Med 2002: 165:A239.
9. Chuang-Tsai, S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Respir Crit Care Med 2003; 167:A462.
10. Lazar MH, Christensen PJ, Du M, Simon RH, Sisson TH. The role of cell proteases and growth factors on the healing of alveolar epithelial cells. Am J Respir Crit Care Med 2003; 167:A392.
11. Teodorescu M, Hanson KE, Peters-Golden M, Simon RH, Sisson TH. Decreased cysteinyl leukotrienes in plasminogen activator inhibitor-1 deficient mice in lung fibrosis. Am J Respir Crit Care Med 2003; 167:A941.
12. Nishiuma T, Sisson TH, Hanson KE, Subbotina N, Simon RH. PAI-1 deficiency causes increased lung epithelial cell plasminogen activator activity and increased MMP-9 activity. Am J Respir Crit Care Med 2003; 167:A191.
13. Sisson TH, Hanson KE, Groskreutz D, Sharma R, Simon RH. Plasminogen activator inhibitor deficiency alters the pattern of injury following bleomycin-induced lung injury. Am J Respir Crit Care Med 2003; 167:A647.
14. Han MK, Sisson TH, Simon RH. Urokinase-type plasminogen activator deficiency worsens pulmonary fibrosis in bleomycin treated mice. Proc Am Thorac Soc 2005; 2:A61.
15. Keena DT, Simon RH, Weiss SJ. Matrix metalloproteinase (MMP)-dependent remodeling of type I collagen by murine lung fibroblasts. Proc Am Thorac Soc 2005; 2:A481.
16. Sisson TH, Yu B, Ling T, Simon RH, Christensen MD. PAI-1 deficiency limits pulmonary fibrosis by improving alveolar repair. Proc Am Thorac Soc 2005; 1:A500.
17. Keena DT, Simon RH, Sabeh F, Weiss SJ. Membrane type I matrix metalloproteinase (MT1-MMP)-dependent remodeling of type I collagen by human lun gifbroblasts. Proc Am Thorac Soc 2006; 1:A441.
18. Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Fibroblast-mediated activation and release of hepatocyte growth factor bound to extracellular matrix. Proc Am Thorac Soc 2006;1A767.
19. Sisson TH, Yu B, Subbotina N, Crandall DL, Simon RH. Antagonism of PAI-1 with PAI-039 reduces pulmonary fibrosis and mortality in mice. Proc Am Thorac Soc 2006;1:A800
20. Krepkovich K, Walker M, Acton J, Joseph P, Simon R. Genetic counseling: Perceptions of cystic fibrosis patients and parents. J Genetic Counseling 2007;16:3.
21. Wettlaufer SH, Moore BB, Phillips K, Simon RH, Sisson TH, Peters-Golden M. Plasminogen activation inhibits lung fibroblast collagen expression via induction of cyclooxygenase-2 and synthesis of prostaglandin E2. Proc Am Thoracic Soc 2008;1:A74..
22. Sisson TH, Courey A, Subbotina N, Christensen PJ, Simon RH. Ablation of type 2 pneumocytes causes pulmonary fibrosis. Proc Am Thorac Soc 2008; 1:A822.
23. White ES, Simon RH, Boore BB, Peters-Golden M, Thannickal VJ. TGF-beta1-induced epithelial-mesenchymal transition is inhibited by prostaglandin E2 via increased intracellular cAMP. Proc Am Thorac Soc 2008;1:A60.
24. Courey AJ, Yu B, Simon RH, Sisson TH. PAI-1 promotes myofibroblast differentiation. Proc Am Thorac Soc 2008;1:A537
25. Courey B, Yu N, Subbotina N, Simon RH, Sisson TH. The vitronectin bindingfunction of PAI-1 is sufficient to induce pulmonary fibrosis. Am Thorac Soc 2009;1:A2710
26. Okunishi K, Huang SK, Wettlaufer MS,Sisson TH, Simon RH, Peters-Golden M. Plasminogen activation system enhances responsiveness to PGE2 in human fibrotic lung fibroblasts. Am Thorac Soc 2009;1:A3459
27. Okunishi K, Huang S, Wettlaufer SH, Sisson TH, Simon RH, Peters-Golden M. Plasminogen activation rescues the protein kinase A signaling impairment in fibrotic human lung fibroblasts. Am Thorac Society 2010;181:A6357
28. Votava J, Belpario J, Kazerooni EA, Lagstein A, Myers JL, Simon RH, Sisson TH, Sundaram B, White ES, Zusman D, Flaherty KR. Utility of transbronchial biopsy versus surgical lung biopsy in the diagnosis of patients with suspected idiopathic interstitial pneumonia. Amer Thorac Soc 2013;
29. Cooling L, Boxer G, Simon R, Hyzy R, Dake L, Butch S, Davenport R.  Whole blood exchange in an adult for life-threatening autoimmune hemolytic anemia. J Clinical Apheresis 2013;28(2):68A.